Fenofibrate has proved to slow the development of diabetic retinopathy and need for laser surgery for people with type 2 diabetes. The purpose of this study is to test whether Fenofibrate is also safe and effective in reducing retinopathy for people with type 1 diabetes.
This trial is accepting participants until June 2024.
Mater researchers in Brisbane are leading a trial of a game-changing flu vaccine that has the potential to provide greater and more durable protection against the virus.
Stephanie Guilas has worked in many departments throughout Mater Hospital Brisbane, however, after 28 years of service, she found her true passion working within Mater Research’s Mothers and Babies...
Working as a research assistant in an immunology research lab, Yvonne Gautam learnt what a clinical trial was after being asked to set up a lab for a Phase Two clinical trial.